Ipigrix tablets 20 mg. №50

$78.00

Manufacturer: Latvia

Diseases of the peripheral nervous system: mono-and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of various etiologies; diseases of the Central nervous system: bulbar paralysis and paresis; recovery period of organic lesions of the Central nervous system, accompanied by motor disorders. Contraindications. Hypersensitivity to ipidacrine or other components of the drug; epilepsy; extrapyramidal disorders with hyperkinesis; angina, severe bradycardia; bronchial asthma; vestibular disorders; peptic ulcer of the stomach or duodenum in the acute stage; mechanical obstruction of the bowel and urinary tract.

Category:

Description

Ipigrix tablets Composition
active substance: ipidacrine;

1 tablet contains 20 mg of ipidacrine hydrochloride (in terms of the anhydrous substance)

excipients: lactose monohydrate, potato starch; calcium stearate.

Ipigrix tablets Dosage form
Pills.

Basic physical and chemical properties: round flat-cylindrical tablets of white or almost white color with a bevel.

Ipigrix tablets Pharmacotherapeutic group
Funds acting on the nervous system. Parasympathomimetics. Anticholinesterase drugs.

ATX code N07A A.

Pharmachologic effect
Ipidacrine is a drug that has a biologically beneficial combination of two molecular effects: blockade of membrane potassium permeability and inhibition of cholinesterase. In this case, the blockade of the potassium permeability of the membrane plays a decisive role.

The blockade of the potassium permeability of the membrane leads, first of all, to the continuation of the repolarization phase of the action potential of the excited membrane and an increase in the activity of the presynaptic axon. This leads to an increase in the entry of calcium ions into the presynaptic terminal, which, in turn, leads to an increase in the release of a mediator into the presynaptic cleft in all synapses. An increase in the concentration of a mediator in the synaptic cleft promotes strong stimulation of the postsynaptic cell due to mediator-receptor interaction. In cholinergic synapses, inhibition of cholinesterase causes an even greater accumulation of the neurotransmitter in the synaptic cleft and an increase in the functional activity of the postsynaptic cell (contraction, conduction of excitation).

Ipidacrine enhances the effect of acetylcholine, adrenaline, serotonin, histamine, oxytocin on smooth muscles.

Ipidacrine exhibits the following pharmacological effects:

stimulation and restoration of neuromuscular transmission;

restoration of impulse conduction in the peripheral nervous system after its blockade by various agents (trauma, inflammation, the action of local anesthetics, some antibiotics, potassium chloride, toxins, etc.);

strengthening of the contractile smooth muscle organs;

specifically moderate stimulation of the central nervous system (CNS) with individual manifestations of sedation;

improving memory and learning ability;

analgesic effect

Ipidacrine has no teratogenic, embryotoxic, mutagenic, carcinogenic, allergenic and immunotoxic effects, and also does not affect the endocrine system.

Pharmacokinetics
After oral administration, it is rapidly absorbed from the digestive tract. The maximum concentration is reached in blood plasma 1:00 after administration. From the blood it quickly enters the tissues, and in the stage of stabilization, only 2% is found in the blood serum, the half-life in the distribution phase is 40 minutes. 40-50% of ipidacrine binds to blood plasma proteins. It is absorbed mainly from the duodenum, slightly less from the small intestine and ileum, only 3% of the dose is absorbed in the stomach. Excretion is carried out through a combination of renal and extrarenal mechanisms (biotransformation, secretion with bile), while secretion with urine predominates. Only 3.7% of the drug is excreted in the urine unchanged, which indicates a rapid metabolism in the body.
Indications
diseases of the peripheral nervous system (neuropathy, neuritis, polyneuritis and polyneuropathy, myelopolyradiculoneuritis), myasthenia gravis and myasthenic syndrome of various etiologies.

Bulbar paralysis and paresis.

Memory impairment of various etiologies (Alzheimer’s disease and other forms of senile mental impairment); mental retardation in children.

The recovery period of organic lesions of the central nervous system, accompanied by movement disorders.

In the complex therapy of multiple sclerosis and other forms of demyelinating diseases of the nervous system.

Intestinal atony.

Contraindications

Hypersensitivity to ipidacrine and / or other components of the drug.

Epilepsy.

Extrapyramidal disorders with hyperkinesis.

Angina pectoris.

Severe bradycardia.

Bronchial asthma.

Vestibular Disorders.

Mechanical obstruction of the intestines and urinary tract.

Peptic ulcer of the stomach or duodenum in the acute stage.